Polycystic ovary syndrome is a condition characterized by obesity, anovulation and hyperandrogenism/hyperandrogenemia. Insulin resistance is common, and treatment is aimed at reducing this.
Conditions
Interventions
Trade Name: Orabet
Product Name: Metformin
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
Organisation name was not entered
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Polycystic ovary syndrome, BMI 30 - 35, age 25 - 35, no hormonal treatment, no diabetes, no contraindications to metformin treatment, not pregnant or breast-feeding, no physical problems making exercise impossible. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Hormonal treatment, diabetes, contraindications to metformin treatment, pregnant or breast-feeding, physical problems making exercise impossible, liver or renal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the effect of medical treatment, i.e. metformin, with the effect of exercise on insulin resistance and quality of life.;Secondary Objective: Change in hormonal and metabolic factors. ;Primary end point(s): Change in insulin resistance and quality of life | — |
Countries
Denmark
Outcome results
None listed